Annual report pursuant to Section 13 and 15(d)

Note 13 - Notes Payable (Details Textual)

Note 13 - Notes Payable (Details Textual)										1 Months Ended								8 Months Ended	12 Months Ended
Note 13 - Notes Payable (Details Textual)	Jan. 16, 2018 USD ($)	Nov. 02, 2017 USD ($)	Mar. 31, 2017 USD ($)	Mar. 03, 2017 USD ($)	Mar. 01, 2017 USD ($)	Jul. 01, 2016	Jun. 22, 2016 USD ($)	May 31, 2016 USD ($) shares	Mar. 31, 2014 USD ($) $ / shares shares	Dec. 31, 2017 USD ($) $ / shares	Nov. 30, 2017 USD ($)	Dec. 31, 2016 USD ($)	Jul. 31, 2016 USD ($) shares	Jul. 31, 2015 USD ($)	May 31, 2015 USD ($) $ / shares	Mar. 31, 2014 USD ($) $ / shares shares	Jun. 30, 2013 USD ($) shares	Dec. 31, 2015 USD ($)	Dec. 31, 2017 USD ($) $ / shares	Dec. 31, 2016 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Jun. 25, 2013 USD ($)	Feb. 28, 2017	Jul. 31, 2014 USD ($)	Jul. 31, 2012 USD ($)
Repayments of Notes Payable																			$ 59,753,740	$ 231,453	$ 30,333,333
Change in Fair Value of Financial Instruments																			153,357	2,858,524	(614,782)
Interest Payable, Current												$ 5,756,519								5,756,519
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares										$ 1.19									$ 1.19
Equity Method Investment, Payment Upon Termination of Joint Venture																				110,000
Interest Expense, Debt																			159,000	5,000	1,300,000
Interest Expense Recorded Related to Amortization of Debt Discounts and Deferred Financing Costs																			134,000		326,000
Disposal Group, Including Discontinued Operation, Interest Expense																			1,706,491	14,856,404	5,603,820
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months										$ 2,400,000									$ 2,400,000
R-NAV [Member]
Repayments of Notes Payable													$ 333,333	$ 333,333
Debt Instrument, Face Amount																										$ 666,666
Equity Method Investment, Payment Upon Termination of Joint Venture								$ 110,000					110,000
Equity Method Investment, Forgiven Promissory Note, Amount								$ 333,333					$ 333,333
R-NAV [Member] \| Preferred Stock [Member]
Equity Method Investment, Shares Transferred Upon Termination of Joint Venture \| shares								1,500,000					1,500,000
R-NAV [Member] \| Common Stock [Member]
Equity Method Investment, Shares Transferred Upon Termination of Joint Venture \| shares								3,500,000					3,500,000
Series KK Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares										$ 1.918									$ 1.918
Minimum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares										0.01									0.01
Maximum [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares										$ 3.04									$ 3.04
Platinum-Montaur Life Sciences LLC Litigation [Member] \| Pending Litigation [Member]
Loss Contingency, Damages Sought, Value		$ 1,914,827.22
CRG Loan Agreement, Ohio Case [Member]
Release of Cash Held in Escrow				$ 2,000,000
CRG Loan Agreement, Texas Case [Member]
Release of Cash Held in Escrow				3,000,000
CRG Loan Agreement, Texas Case [Member] \| Pending Litigation [Member] \| Subsequent Event [Member]
Loss Contingency, Damages Awarded,Value, Requested Modified Amount	$ 2,900,000
CRG Loan Agreement, Texas Case [Member] \| Judicial Ruling [Member]
Loss Contingency, Damages Awarded, Value, Additional Amount				7,000,000						$ 7,000,000
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration										4,100,000
CRG Loan Agreement, Texas Case [Member] \| Judicial Ruling [Member] \| Subsequent Event [Member]
Loss Contingency, Damages Awarded, Value, Amount not Taken into Consideration	$ 4,100,000
CRG Loan Agreement, Texas Case [Member] \| Judicial Ruling [Member] \| Maximum [Member]
Loss Contingency, Damages Awarded, Value				66,000,000						66,000,000
Federal Funds Rate [Member] \| R-NAV [Member]
Debt Instrument, Interest Rate, Stated Percentage																										0.31%
Platinum-Montaur Life Sciences LLC Litigation [Member]
Line of Credit Facility, Maximum Borrowing Capacity																											$ 50,000,000
Line of Credit Facility, Current Borrowing Capacity																	$ 35,000,000										35,000,000
Line of Credit Facility, Increase Additional Borrowings Terms Not Negotiated																											15,000,000
Proceeds from Lines of Credit																				0	4,500,000	$ 0	$ 4,000,000	$ 8,000,000
Debt Instrument, Interest Rate, Stated Percentage									10.00%						10.00%	10.00%	10.00%
InterestRateInAdditionToAmendedAgreement																	0.125%
Percentage of VWAP for Conversion Calculation																	90.00%
Period of Preceding Date of Conversion Request																	10 days
Minimum Revenue from Sales and Licensing for Mandatory Repayment Due																	$ 2,000,000
Repayments of Notes Payable																	$ 4,800,000
Stock for Stock Conversion Number of Shares Converted \| shares																	2,364.9
Number of Common Shares Underlying Series B Preferred Stock \| shares																	7,733,223
Shares Conversion, Number of Common Stock Equivalent to Each Preferred Stock \| shares																	3,270
Debt Instrument, Convertible, Threshold Trading Days															10
Debt Instrument, Convertible, Stock Price Trigger \| $ / shares															$ 2.53
Embedded Derivative, Fair Value of Embedded Derivative Liability												153,000								153,000
Change in Fair Value of Financial Instruments																				2,900,000	(615,000)
Convertible Debt, Fair Value Disclosures										2,000,000		9,600,000							$ 2,000,000	9,600,000
Interest Expense, Debt, Excluding Amortization																			265,000	1,000,000	761,000
Line of Credit Facility, Decrease Forgiveness Interest Percentage						6.00%
Platinum-Montaur Life Sciences LLC Litigation [Member] \| Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate															6.75%	6.75%	6.75%
Platinum-Montaur Life Sciences LLC Litigation [Member] \| Oxford Financing Rate [Member]
Debt Instrument, Basis Spread on Variable Rate									0.125%
Platinum-Montaur Life Sciences LLC Litigation [Member] \| Interest Rate Pursuant to CRG Term Loan [Member]
Debt Instrument, Basis Spread on Variable Rate															0.125%
Platinum Loan Agreement [Member] \| PPCO [Member]
Line of Credit Facility, Maximum Borrowing Capacity																											$ 50,000,000
Embedded Derivative, Fair Value of Embedded Derivative Liability										$ 0									0
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease)																			$ (153,000)
Repayments of Debt				7,700,000
Convertible Debt				1,900,000
Term Loan Agreement [Member] \| Cardinal Health 414 [Member]
Letters of Credit Outstanding, Amount				7,000,000
Term Loan Agreement [Member] \| CRG [Member]
Letters of Credit Outstanding, Amount				12,000,000
Term Loan Agreement [Member] \| CRG [Member]
Debt Instrument, Interest Rate, Stated Percentage															14.00%										14.00%
Interest Expense, Debt, Excluding Amortization																				553,000	1,300,000
Repayments of Debt				59,000,000
Debt Instrument, Face Amount															$ 50,000,000
Debt Instrument, Additional Loans That May Be Made Available Upon the Satisfaction of Certain Conditions															$ 10,000,000
Percentage of Per Annum Interest Paying in Cash															10.00%
Percentage of Per Annum Interest as Compounded Interest															4.00%
Debt Instrument, Number of Quarterly Payments															8
Debt Instrument Payment Terms Payment Period															2 years
Notes Payable												51,700,000						$ 51,300,000		51,700,000	51,300,000
Debt Instrument, Unamortized Discount (Premium), Net															$ 2,200,000
Debt Instrument End of Term Fee, Amount															1,000,000
Debt Instrument, Fee Amount															1,000,000
Debt Instrument, Covenant Compliance, Income (Loss) Earnings Before Interest, Taxes, Depreciation, and Amortization, Minimum															5,000,000
Debt Instrument, Covenant Compliance Sales Revenue Minimum Next Twelve Months												22,500,000								22,500,000
DebtInstrumentCovenantComplianceTargetRevenueMinimum															$ 45,000,000
Debt Instrument, Covenant Compliance Cure Right Ratio															2.5
Debt Instrument, Covenant Compliance Liquidity Minimum															$ 5,000,000
Debt Instrument, Interest Rate in the Event of Default															18.00%
Primary Bank Account Cash Taken Possession Of By Creditor							$ 4,100,000
Payments to Prepayment Premium and Backend Facility Fee on Claims of Default							3,900,000
Payments to Principal Balance of Debt on Claims of Default							$ 189,000
Debt Instrument, Final Payoff Amount, Threshold Above Which the Reporting Entity Will First Pay Without Resorting to Letter of Credit				59,000,000
Term Loan Agreement [Member] \| CRG [Member] \| Minimum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount				47,000,000
Term Loan Agreement [Member] \| CRG [Member] \| Maximum [Member]
Debt Instrument, Agreed-upon Final Payoff Amount				66,000,000
Term Loan Agreement [Member] \| CRG [Member] \| Accrued Liabilities and Other [Member]
Interest Payable, Current												$ 5,800,000						0		$ 5,800,000	$ 0
Term Loan Agreement [Member] \| CRG [Member] \| CRG Loan Agreement, Texas Case [Member] \| Judicial Ruling [Member]
Repayments of Debt			$ 59,000,000	$ 59,000,000	$ 59,000,000
Oxford Finance, LLC [Member]
Debt Instrument, Interest Rate, Stated Percentage									8.50%							8.50%
Debt Instrument, Face Amount									$ 30,000,000							$ 30,000,000
Debt Instrument, Unamortized Discount (Premium), Net									3,000,000							3,000,000
Debt Instrument End of Term Fee, Amount																		$ 2,400,000
Repayments of Long-term Debt															$ 31,700,000
Debt Instrument, Early Redemption Fee Amount															$ 289,000
Oxford Finance, LLC [Member] \| Series KK Warrants [Member]
Debt Instrument, Unamortized Discount (Premium), Net									$ 120,000							$ 120,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights \| shares									391,032							391,032
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares									$ 1.918							$ 1.918
Notes Payable Issued for Prepayment of Insurance Premiums [Member] \| IPFS [Member]
Debt Instrument, Interest Rate, Stated Percentage											4.00%	8.99%								8.99%
Debt Instrument, Face Amount											$ 396,000	$ 348,000								$ 348,000
Debt Instrument, Term											10 years	240 days
Debt Instrument, Periodic Payment											$ 40,000	$ 45,000